Published September 21, 2022
Newswire and other websites report that UB spinoff POP Biotechnologies announced the start of two phase 3 clinical studies of EuCorVac-19, a COVID-19 vaccine candidate the startup is developing with South Korean partner EuBiologics.
The technology behind the vaccine comes from the lab of UB faculty member Jonathan Lovell, a POP Biotechnologies co-founder and SUNY Empire Innovation Associate Professor of biomedical engineering.
